Armata Pharmaceuticals, Inc. (ARMP)
2.98
-0.19
(-5.99%)
USD |
NYAM |
Nov 19, 16:00
Armata Pharmaceuticals Cash from Operations (Quarterly) : -5.516M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -5.516M |
| June 30, 2026 | -8.666M |
| March 31, 2026 | -5.782M |
| December 31, 2025 | -6.674M |
| September 30, 2025 | -4.298M |
| June 30, 2025 | -7.211M |
| March 31, 2025 | -7.58M |
| December 31, 2024 | -7.927M |
| September 30, 2024 | -8.863M |
| June 30, 2024 | -10.18M |
| March 31, 2024 | -10.58M |
| December 31, 2023 | -8.106M |
| September 30, 2023 | -9.687M |
| June 30, 2023 | -12.06M |
| March 31, 2023 | -17.57M |
| December 31, 2022 | -10.48M |
| September 30, 2022 | -10.33M |
| June 30, 2022 | -8.148M |
| March 31, 2022 | -3.515M |
| December 31, 2021 | -8.598M |
| September 30, 2021 | -4.964M |
| June 30, 2021 | -4.538M |
| March 31, 2021 | -5.475M |
| December 31, 2020 | -6.302M |
| September 30, 2020 | -3.88M |
| Date | Value |
|---|---|
| June 30, 2020 | -3.856M |
| March 31, 2020 | -4.232M |
| December 31, 2019 | -2.729M |
| September 30, 2019 | -4.567M |
| June 30, 2019 | -5.827M |
| March 31, 2019 | -2.459M |
| December 31, 2018 | -3.195M |
| September 30, 2018 | -2.02M |
| June 30, 2018 | -1.876M |
| March 31, 2018 | -3.536M |
| December 31, 2017 | -2.369M |
| September 30, 2017 | -0.593M |
| June 30, 2017 | -2.931M |
| March 31, 2017 | -3.299M |
| December 31, 2016 | -1.481M |
| September 30, 2016 | -3.131M |
| June 30, 2016 | -2.892M |
| March 31, 2016 | -3.085M |
| December 31, 2015 | -2.317M |
| September 30, 2015 | -2.497M |
| June 30, 2015 | -2.662M |
| March 31, 2015 | -2.305M |
| December 31, 2014 | -3.20M |
| September 30, 2014 | -2.627M |
| June 30, 2014 | -3.058M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Lineage Cell Therapeutics, Inc. | -5.62M |
| Voyager Therapeutics, Inc. | -19.67M |
| Black Diamond Therapeutics, Inc. | -8.338M |
| Invivyd, Inc. | -32.11M |
| Elicio Therapeutics, Inc. | -10.36M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.091M |
| Cash from Financing (Quarterly) | -0.028M |
| Free Cash Flow | -26.86M |
| Free Cash Flow Per Share (Quarterly) | -0.0895 |
| Free Cash Flow to Equity (Quarterly) | 56.76M |
| Free Cash Flow to Firm (Quarterly) | 1.954M |
| Free Cash Flow Yield | -24.24% |